Despite of the recent advances in personalized medicine, the majority of patients with metastatic colorectal cancer still succumb to disease progression, with liver failure constituting one of the most common causes of death. Recently, selective internal radioembolization has emerged as a new treatment option in patients with liver predominant disease. The concurrent administration of yttrium-90 (Y-90) SIR-Spheres® (SIRTEX, Sydney, Australia) microspheres and chemotherapy has been linked to significant improvements in response rate, time to intrahepatic tumor progression and overall survival. In this manuscript, the author provides his personal perspective on the current clinical evidence in support of SIR-Spheres liver embolization and reflects on the potential of this treatment in various stages of treatment of metastatic colorectal cancer.
Click here to view full article.